AAV-RPGR Gene Therapy Rescues Opsin Mislocalisation in a Human Retinal Organoid Model of RPGR-Associated X-Linked Retinitis Pigmentosa
Authors:
- Paul E. SladenPSPaul E. Sladen
- Arifa NaeemANArifa Naeem
- Toyin Adefila-IdeozuTAToyin Adefila-Ideozu
- Tijmen VermeuleTVTijmen Vermeule
- Sophie L. BussonSBSophie L. Busson
- Michel MichaelidesMMMichel Michaelides
- Stuart NaylorSNStuart Naylor
- Alexandria ForbesAFAlexandria Forbes
- Amelia LaneALAmelia Lane
- Anastasios GeorgiadisAGAnastasios Georgiadis
Open Access
- 2 February 2024
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (3) , 1839
Abstract
Variants within the Retinitis Pigmentosa GTPase regulator (RPGR) gene are the predominant cause of X-Linked Retinitis Pigmentosa (XLRP), a common and severe form of inherited retinal disease. XLRP is characterised by the progressive degeneration and loss of photoreceptors, leading to visual loss and, ultimately, bilateral blindness. Unfortunately, there are no effective approved treatments for RPGR-associated XLRP. We sought to investigate the efficacy of RPGRORF15 gene supplementation using a clinically relevant construct in human RPGR-deficient retinal organoids (ROs). Isogenic RPGR knockout (KO)-induced pluripotent stem cells (IPSCs) were generated using established CRISPR/Cas9 gene editing methods targeting RPGR. RPGR-KO and isogenic wild-type IPSCs were differentiated into ROs and utilised to test the adeno associated virus (AAV) RPGR (AAV-RPGR) clinical vector construct. The transduction of RPGR-KO ROs using AAV-RPGR successfully restored RPGR mRNA and protein expression and localisation to the photoreceptor connecting cilium in rod and cone photoreceptors. Vector-derived RPGR demonstrated equivalent levels of glutamylation to WT ROs. In addition, treatment with AAV-RPGR restored rhodopsin localisation within RPGR-KO ROs, reducing mislocalisation to the photoreceptor outer nuclear layer. These data provide mechanistic insights into RPGRORF15 gene supplementation functional potency in human photoreceptor cells and support the previously reported Phase I/II trial positive results using this vector construct in patients with RPGR-associated XLRP, which is currently being tested in a Phase III clinical trial.Keywords
Funding Information
- MeiraGTx
This publication has 33 references indexed in Scilit:
- Human pluripotent-stem-cell-derived organoids for drug discovery and evaluationCell Stem Cell, 2023
- Antioxidant and lipid supplementation improve the development of photoreceptor outer segments in pluripotent stem cell-derived retinal organoidsStem Cell Reports, 2022
- Detailed comparison of phenotype between male patients carrying variants in exons 1–14 and ORF15 of RPGRExperimental Eye Research, 2020
- Splice-Modulating Oligonucleotide QR-110 Restores CEP290 mRNA and Function in Human c.2991+1655A>G LCA10 ModelsMolecular Therapy Nucleic Acids, 2018
- Gene Correction Reverses Ciliopathy and Photoreceptor Loss in iPSC-Derived Retinal Organoids from Retinitis Pigmentosa PatientsStem Cell Reports, 2018
- Simultaneous Reprogramming and Gene Correction of Patient FibroblastsStem Cell Reports, 2015
- Photoreceptor rescue by an abbreviated human RPGR gene in a murine model of X-linked retinitis pigmentosaGene Therapy, 2015
- RPGR: Its role in photoreceptor physiology, human disease, and future therapiesExperimental Eye Research, 2015
- Localizing the RPGR protein along the cilium: a new method to determine efficacies to treat RPGR mutationsGene Therapy, 2015
- Mutational hot spot within a new RPGR exon in X-linked retinitis pigmentosaNature Genetics, 2000